
The London Stock Exchange Group’s (LSE) US$27 billion purchase of Refinitiv has reportedly already come under intense scrutiny in Brussels, raising the prospect that EU regulators will initiate a much longer investigation into the deal than had been expected.
The two companies are yet to formally notify competition regulators of the deal, which would trigger the review of the bourse’s acquisition of the financial data provider, which was first announced in August last year, reported The Financial Times.
The LSE and Refinitiv had planned to do so by the start of February, but have delayed after the deal came under unexpected scrutiny in the so-called pre-notification phase, the Financial Times reported.
The proposed tie-up, which has been welcomed by LSE shareholders, was not expected to face significant regulatory hurdles, and the companies had indicated it would complete by the second half of this year.
But the LSE and Refinitiv are now gearing up for a protracted legal battle over the deal, according to the FT.
A lengthy pre-notification period often indicates that regulators will launch a lengthy probe faced by only a minority of the deals, and raises the risk that they could intervene to block the acquisition.
“The deal is likely to go into a lengthier probe and we are not on the clock yet,” one person involved in the discussions told the FT. “It could spill into next year.”
Advisers to the LSE are frustrated by the number of questions being asked by regulators at this early stage, a source told the paper, adding that the process was making their lives “too miserable.”
Full Content: Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU Civil Society Groups and Labor Unions Raise Alarm Over Proposed Changes to GDPR
May 19, 2025 by
CPI
EU Antitrust Regulators Push Back Deadline on UniCredit’s Takeover Bid for Banco BPM
May 19, 2025 by
CPI
Intel Challenges €376 Million EU Fine in Ongoing Antitrust Dispute
May 19, 2025 by
CPI
Red Bull Challenges EU Commission Over Lengthy Antitrust Inspection
May 19, 2025 by
CPI
Live Nation Under Criminal Antitrust Investigation Over Pandemic-Era Refund Policies
May 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas